Stay updated with breaking news from Oncodermatology Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Crystal Lake, Illinois, November 21, 2023 - Aptar Digital Health, a global expert in Software as a Medical Device (SaMD), digital Patient Support Programs (PSPs) and disease management solutions, today announced the expansion of its Oncology Clinical Advisory Board. Comprised of leading clinical, oncology and digita...
/PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid...
Lutris Pharma Phase 1 Results of LUT014 for Skin Toxicities Associated with Treatment of Colorectal Cancer Patients with EGFR Inhibitors Published in Cancer Discovery USA - English LUT014 was found to be safe and effective LUT014 Phase 2 trial designed to include 117 patients in 20 centers in the US and Israel has been initiated News provided by Share this article Share this article TEL AVIV, Israel, April 28, 2021 /PRNewswire/ -- Lutris Pharma, a clinical stage biopharmaceutical company focusing on improving anti-cancer therapies by reducing dose limiting side effects, announced today that ...
Share this article Share this article SAN DIEGO, March 3, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced the appointment of Mario Lacouture, M.D. to the REM-001 Scientific Advisory Board with the initial focus in Cutaneous Metastatic Breast Cancer (CMBC). "We are pleased to welcome Dr. Lacouture to our CMBC focused Scientific Advisory Board as we prepare REM-001, our photodynamic therapy platform, for late-stage pivotal testing in this debi...